Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications.

G protein-coupled receptors (GPCRs) represent a major class of proteins in the genome of many species, including humans. In addition to the mapping of a number of human disorders to regions of the genome containing GPCRs, a growing body of literature has documented frequently occurring variations (i.e. polymorphisms) in GPCR loci. In this article, we use a domain-based approach to systematically examine examples of genetic variation in the coding and noncoding regions of GPCR loci. Data to date indicate that residues in GPCRs are involved in ligand binding and coupling to G proteins and that regulation can be altered by polymorphisms. Studies of GPCR polymorphisms have also uncovered the functional importance of residues not previously implicated from other approaches that are involved in the function of GPCRs. We predict that studies of GPCR polymorphisms will have a significant impact on medicine and pharmacology, in particular, by providing new means to subclassify patients in terms of both diagnosis and treatment.

[1]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[2]  D. O'Connor,et al.  β2-Adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. , 2000 .

[3]  M. Bouvier,et al.  Export from the Endoplasmic Reticulum Represents the Limiting Step in the Maturation and Cell Surface Expression of the Human δ Opioid Receptor* , 2000, The Journal of Biological Chemistry.

[4]  R. Leurs,et al.  The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. , 2000, Molecular pharmacology.

[5]  U. Kumar,et al.  Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.

[6]  S. Angers,et al.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.

[7]  M. R. Adams,et al.  Comparative genomics of the eukaryotes. , 2000, Science.

[8]  P. Goldman-Rakic,et al.  Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. , 2000, Science.

[9]  S. Liggett β2-Adrenergic Receptor Pharmacogenetics , 2000 .

[10]  A. Schonbrunn,et al.  Protein Kinase C Activation Stimulates the Phosphorylation and Internalization of the sst2A Somatostatin Receptor* , 2000, The Journal of Biological Chemistry.

[11]  A. Scheer,et al.  Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation. , 2000, Molecular pharmacology.

[12]  U. Gether Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[13]  Z. Vogel,et al.  Role of the highly conserved Asp‐Arg‐Tyr motif in signal transduction of the CB2 cannabinoid receptor , 2000, FEBS letters.

[14]  R. Hermosilla,et al.  The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues , 2000, FEBS letters.

[15]  J. Mollon,et al.  A cluster of single nucleotide polymorphisms in the 5′-leader of the human dopamine D3 receptor gene (DRD3) and its relationship to schizophrenia , 2000, Neuroscience Letters.

[16]  T Fenyvesi,et al.  Angiotensin II type 1 receptor gene polymorphism and mitral valve prolapse syndrome. , 2000, American heart journal.

[17]  S. Liggett beta(2)-adrenergic receptor pharmacogenetics. , 2000, American journal of respiratory and critical care medicine.

[18]  Qing Yang,et al.  Expression and Function of the Gonadotropin-releasing Hormone Receptor Are Dependent on a Conserved Apolar Amino Acid in the Third Intracellular Loop* , 1999, The Journal of Biological Chemistry.

[19]  K. Thai,et al.  Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. , 1999, Kidney international.

[20]  M. Polak Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene. , 1999, Archives of medical research.

[21]  Liaoyuan A. Hu,et al.  Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Hubbard,et al.  Association of CCR5 ▵32 with reduced risk of asthma , 1999, The Lancet.

[23]  D StClair,et al.  -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. , 1999, American journal of medical genetics.

[24]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[25]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[26]  P Ghanouni,et al.  Mutation of a highly conserved aspartic acid in the beta2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. , 1999, Molecular pharmacology.

[27]  M. Parmentier,et al.  Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants , 1999, British journal of pharmacology.

[28]  F Skrabal,et al.  beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. , 1999, Hypertension.

[29]  R. Detels,et al.  Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. , 1999, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  Thomas Gudermann,et al.  Structural basis of G protein-coupled receptor function , 1999, Molecular and Cellular Endocrinology.

[31]  Kenneth A. Jacobson,et al.  The Role of Amino Acids in Extracellular Loops of the Human P2Y1 Receptor in Surface Expression and Activation Processes* , 1999, The Journal of Biological Chemistry.

[32]  T. Arinami,et al.  A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. , 1999, Biochemical and biophysical research communications.

[33]  K. Palczewski,et al.  β-Arrestin-dependent Desensitization of Luteinizing Hormone/Choriogonadotropin Receptor Is Prevented by a Synthetic Peptide Corresponding to the Third Intracellular Loop of the Receptor* , 1999, The Journal of Biological Chemistry.

[34]  D. Thomason,et al.  Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics , 1999, Clinical pharmacology and therapeutics.

[35]  A. Koyanagi,et al.  Polymorphism in the 5'-leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.

[36]  J. Bockaert,et al.  Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.

[37]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[38]  Colleen M. Niswender,et al.  RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.

[39]  J. Bockaert,et al.  Molecular tinkering of G protein‐coupled receptors: an evolutionary success , 1999, The EMBO journal.

[40]  D. Hewett‐Emmett,et al.  High polymorphism at the human melanocortin 1 receptor locus. , 1999, Genetics.

[41]  P. Insel,et al.  Human adrenoceptor polymorphisms: evolving recognition of clinical importance. , 1999, Trends in pharmacological sciences.

[42]  I. Hall,et al.  β2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting β2-agonist therapy , 1999 .

[43]  K. Ohara,et al.  Schizophrenia and the serotonin-2A receptor promoter polymorphism , 1999, Psychiatry Research.

[44]  I. Hall,et al.  Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients. , 1999, Chest.

[45]  I. Hall,et al.  Identification of novel polymorphisms within the promoter region of the human β2 adrenergic receptor gene , 1999, British journal of pharmacology.

[46]  M. Caron,et al.  Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features. , 1999, Molecular pharmacology.

[47]  I. Hall,et al.  Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy. , 1999, Clinical science.

[48]  R. Hubbard,et al.  Association of CCR5 delta32 with reduced risk of asthma. , 1999, Lancet.

[49]  J. Haines,et al.  Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. , 1999, Pharmacogenetics.

[50]  Y. Totsuka,et al.  A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. , 1999, The Journal of clinical endocrinology and metabolism.

[51]  E. Fleck,et al.  Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21M). , 1998, American journal of medical genetics.

[52]  Cori Bargmann Neurobiology of the Caenorhabditis elegans genome. , 1998, Science.

[53]  J. Wess,et al.  Molecular basis of receptor/G-protein-coupling selectivity. , 1998, Pharmacology & therapeutics.

[54]  S. Liggett,et al.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. , 1998, The Journal of clinical investigation.

[55]  J. Bockaert,et al.  5‐HT4 Receptors: Gene, Transduction and Effects on Olfactory Memory , 1998, Annals of the New York Academy of Sciences.

[56]  T. Pawson,et al.  SH3 binding domains in the dopamine D4 receptor. , 1998, Biochemistry.

[57]  N. Cotte,et al.  Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor* , 1998, The Journal of Biological Chemistry.

[58]  V. Álvarez,et al.  Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. , 1998, Cardiovascular research.

[59]  K. Clément,et al.  A frameshift mutation in human MC4R is associated with a dominant form of obesity , 1998, Nature Genetics.

[60]  S. O’Rahilly,et al.  A frameshift mutation in MC4R associated with dominantly inherited human obesity , 1998, Nature Genetics.

[61]  C. Kleeberger,et al.  CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.

[62]  E. Brown,et al.  Dimerization of the Extracellular Calcium-sensing Receptor (CaR) on the Cell Surface of CaR-transfected HEK293 Cells* , 1998, The Journal of Biological Chemistry.

[63]  D. Bikle,et al.  The Calcium Sensing Receptor and Its Alternatively Spliced Form in Keratinocyte Differentiation* , 1998, The Journal of Biological Chemistry.

[64]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Robert J. Lefkowitz,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[66]  B. Kobilka,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[67]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[68]  E. Brown,et al.  Familial hypoparathyroidism: identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. , 1998, The Journal of clinical endocrinology and metabolism.

[69]  T. Wienker,et al.  Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. , 1998, Kidney international.

[70]  M. Yanagisawa,et al.  Novel Mutations of the Endothelin B Receptor Gene in Patients with Hirschsprung’s Disease and Their Characterization* , 1998, The Journal of Biological Chemistry.

[71]  W. Rosenthal,et al.  The molecular basis of nephrogenic diabetes insipidus , 1998, Journal of Molecular Medicine.

[72]  J. Friedman,et al.  Desensitization of β2-Adrenergic Receptors with Mutations of the Proposed G Protein-coupled Receptor Kinase Phosphorylation Sites* , 1998, The Journal of Biological Chemistry.

[73]  K. Kameyama,et al.  Internalization and Down-regulation of Human Muscarinic Acetylcholine Receptor m2 Subtypes , 1998, The Journal of Biological Chemistry.

[74]  L. Romics,et al.  Association of angiotensin II type 1 receptor polymorphism with resistant essential hypertension. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[75]  H. V. Van Tol Structural and functional characteristics of the dopamine D4 receptor. , 1998, Advances in pharmacology.

[76]  M. Birnbaumer,et al.  Mutations of the DRY motif that preserve beta 2-adrenoceptor coupling. , 1998, Receptors & channels.

[77]  M. Bouvier,et al.  Structural and functional aspects of G protein-coupled receptor oligomerization. , 1998, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[78]  D. Collier,et al.  Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine , 1998, Molecular Psychiatry.

[79]  R. Erickson,et al.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.

[80]  R. Paschke,et al.  Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. , 1997, The Journal of clinical endocrinology and metabolism.

[81]  L. Devi,et al.  Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.

[82]  Marc Parmentier,et al.  The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.

[83]  M. Caulfield,et al.  Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor. , 1997, Hypertension.

[84]  N. Martin,et al.  Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. , 1997, Human molecular genetics.

[85]  I. Gantz,et al.  Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor)* , 1997, The Journal of Biological Chemistry.

[86]  Tao Li,et al.  Association between 5-HT2A gene promoter polymorphism and anorexia nervosa , 1997, The Lancet.

[87]  K. Ray,et al.  Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor. , 1997, The Journal of clinical endocrinology and metabolism.

[88]  K. Eidne,et al.  An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation. , 1997, Endocrinology.

[89]  D. Goldman,et al.  Agonist-Promoted Down-Regulation and Functional Desensitization in Two Naturally Occurring Variants of the Human Serotonin1A Receptor , 1997, Neuropsychopharmacology.

[90]  P. Seeburg,et al.  Interaction of ion channels and receptors with PDZ domain proteins , 1997, Current Opinion in Neurobiology.

[91]  P. Insel,et al.  Decreased transcript expression coincident with impaired glycosylation in the beta2-adrenergic receptor gene does not result from differences in the primary sequence. , 1997, Biochimica et biophysica acta.

[92]  M. Kozak,et al.  Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6 , 1997, The EMBO journal.

[93]  M. Nöthen,et al.  Human 5-HT5AReceptor Gene: Systematic Screening for DNA Sequence Variation and Linkage Mapping on Chromosome 7q34–q36 Using a Polymorphism in the 5′ Untranslated Region , 1997 .

[94]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[95]  R. Scully,et al.  A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. , 1997, The Journal of clinical endocrinology and metabolism.

[96]  C. Barnes,et al.  Homer: a protein that selectively binds metabotropic glutamate receptors , 1997, Nature.

[97]  B. Morris,et al.  Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension , 1997, Clinical genetics.

[98]  H. V. Van Tol,et al.  Structural and Functional Characteristics of the Dopamine D4 Receptor , 1997 .

[99]  M. Nöthen,et al.  Human 5-HT5A receptor gene: systematic screening for DNA sequence variation and linkage mapping on chromosome 7q34-q36 using a polymorphism in the 5' untranslated region. , 1997, Biochemical and biophysical research communications.

[100]  E. Brown,et al.  In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. , 1997, The Journal of clinical investigation.

[101]  R. Devés,et al.  Changes in Membrane and Surface Potential Explain the Opposite Effects of Low Ionic Strength on the Two Lysine Transporters of Human Erythrocytes* , 1996, The Journal of Biological Chemistry.

[102]  A. Couvineau,et al.  Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP‐1, and Other Members of Their New Family of G Protein‐Linked Receptors: Structure‐Function Relationship with Special Reference to the Human VIP‐1 Receptor a , 1996, Annals of the New York Academy of Sciences.

[103]  D. Sibley,et al.  Functional Analysis of the Human D2 Dopamine Receptor Missense Variants* , 1996, The Journal of Biological Chemistry.

[104]  S. Karnik,et al.  Modulation of GDP Release from Transducin by the Conserved Glu134-Arg135 Sequence in Rhodopsin* , 1996, The Journal of Biological Chemistry.

[105]  N. Elshourbagy,et al.  Molecular Characterization of a Novel Human Endothelin Receptor Splice Variant* , 1996, The Journal of Biological Chemistry.

[106]  M. Coulthard,et al.  A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. , 1996, The New England journal of medicine.

[107]  W. Müller-Esterl,et al.  Palmitoylation of Endothelin Receptor A , 1996, The Journal of Biological Chemistry.

[108]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[109]  H. Hwu,et al.  No association of dopamine D2 receptor molecular variant Cys311 and schizophrenia in Chinese patients. , 1996, American journal of medical genetics.

[110]  Michel Bouvier,et al.  A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.

[111]  G. Tsujimoto,et al.  α1a‐Adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy , 1996 .

[112]  A. Helenius,et al.  Glycan-dependent and -independent Association of Vesicular Stomatitis Virus G Protein with Calnexin* , 1996, The Journal of Biological Chemistry.

[113]  S. Liggett,et al.  Chimeric Mutagenesis of Putative G-protein Coupling Domains of the α2A-Adrenergic Receptor , 1996, The Journal of Biological Chemistry.

[114]  K. Kidd,et al.  The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus , 1996, Human Genetics.

[115]  Michael G. Davis,et al.  Mutagenic Analysis of Platelet Thromboxane Receptor Cysteines , 1996, The Journal of Biological Chemistry.

[116]  P. Puri,et al.  Novel mutations of the endothelin-B receptor gene in isolated patients with Hirschsprung's disease. , 1996, Human molecular genetics.

[117]  V. Chhajlani,et al.  Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor. , 1996, Biochemical and biophysical research communications.

[118]  P. Seeman,et al.  Dopamine D4 receptor variant in Africans, D4valine194glycine, is insensitive to dopamine and clozapine: report of a homozygous individual. , 1996, American journal of medical genetics.

[119]  G. Tsujimoto,et al.  Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. , 1996, British journal of pharmacology.

[120]  S. Liggett,et al.  Chimeric mutagenesis of putative G-protein coupling domains of the alpha2A-adrenergic receptor. Localization of two redundant and fully competent gi coupling domains. , 1996, The Journal of biological chemistry.

[121]  S. Pearce,et al.  Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. , 1995, The Journal of clinical investigation.

[122]  Y. Mori,et al.  Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus. , 1995, The Journal of clinical investigation.

[123]  S. Daiger,et al.  Correlation of phenotype with genotype in inherited retinal degeneration , 1995 .

[124]  M. J. Arranz,et al.  Association between clozapine response and allelic variation in 5-HT2A receptor gene , 1995, The Lancet.

[125]  D. Goldman,et al.  Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). , 1995, Genomics.

[126]  S. Green,et al.  Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. , 1995, The Journal of clinical investigation.

[127]  E. Mariman,et al.  Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene , 1995, Nature Genetics.

[128]  J. Dimsdale,et al.  Racial Differences in Epinephrine and β2-Adrenergic Receptors , 1995 .

[129]  J. Dimsdale,et al.  Racial differences in epinephrine and beta 2-adrenergic receptors. , 1995, Hypertension.

[130]  Masashi Yanagisawa,et al.  A missense mutation of the endothelin-B receptor gene in multigenic hirschsprung's disease , 1994, Cell.

[131]  S. Higuchi,et al.  Association of structural polymorphism of the dopamine D2 receptor gene and alcoholism. , 1994, Biochemical and biophysical research communications.

[132]  R. Clark,et al.  cAMP-dependent protein kinase and protein kinase C consensus site mutations of the beta-adrenergic receptor. Effect on desensitization and stimulation of adenylylcyclase. , 1994, The Journal of biological chemistry.

[133]  S. Green,et al.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.

[134]  L. Tiret,et al.  Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. , 1994, Hypertension.

[135]  D. Bichet,et al.  Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant. , 1994, Cellular and molecular biology.

[136]  R. Lefkowitz,et al.  A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[137]  M. Itokawa,et al.  Association of dopamine D2 receptor molecular variant with schizophrenia , 1994, The Lancet.

[138]  Hongtao Yu,et al.  Structural basis for the binding of proline-rich peptides to SH3 domains , 1994, Cell.

[139]  R. Graham,et al.  The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. , 1994, The Journal of biological chemistry.

[140]  E. El-Fakahany,et al.  An arginine residue conserved in most G protein-coupled receptors is essential for the function of the m1 muscarinic receptor. , 1994, Molecular pharmacology.

[141]  L. Birnbaumer,et al.  Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. , 1994, Molecular pharmacology.

[142]  B. Kobilka,et al.  The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. , 1994, The Journal of biological chemistry.

[143]  K. Blum,et al.  No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. , 1994, JAMA.

[144]  R. Lefkowitz,et al.  Erratum: Constitutively active mutants of the α2-adrenergic receptor (Journal of Biological Chemistry (1993) 268 (16483-16487)) , 1994 .

[145]  C. M. Davenport,et al.  Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. , 1993, The Journal of biological chemistry.

[146]  M. Itokawa,et al.  A structural polymorphism of human dopamine D2 receptor, D2(Ser311-->Cys). , 1993, Biochemical and biophysical research communications.

[147]  R. Cotton,et al.  A new codon 15 rhodopsin gene mutation in autosomal dominant retinitis pigmentosa is associated with sectorial disease. , 1993, Archives of ophthalmology.

[148]  J. Kleinman,et al.  Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. , 1993, Archives of general psychiatry.

[149]  R. Lefkowitz,et al.  Constitutively active mutants of the alpha 2-adrenergic receptor. , 1993, The Journal of biological chemistry.

[150]  J. Ott,et al.  Molecular analysis and genetic mapping of the rhodopsin gene in families with autosomal dominant retinitis pigmentosa. , 1993, Genomics.

[151]  J. Wess,et al.  Functional role of proline and tryptophan residues highly conserved among G protein‐coupled receptors studied by mutational analysis of the m3 muscarinic receptor. , 1993, The EMBO journal.

[152]  R Pickens,et al.  Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. , 1992, Archives of general psychiatry.

[153]  C. Fraser,et al.  Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. , 1992, The Journal of biological chemistry.

[154]  M. Caron,et al.  Discrete amino acid sequences of the alpha 1-adrenergic receptor determine the selectivity of coupling to phosphatidylinositol hydrolysis. , 1992, The Journal of biological chemistry.

[155]  M. Caron,et al.  Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. , 1992, The Journal of biological chemistry.

[156]  D. Rutledge Are There Beta-Adrenergic Receptor Response Differences between Racial Groups? , 1991, DICP : the annals of pharmacotherapy.

[157]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[158]  K. Blum,et al.  Allelic association of human dopamine D2 receptor gene in alcoholism. , 1990, JAMA.

[159]  D. Grandy,et al.  Cloning of the cDNA and gene for a human D2 dopamine receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[160]  M. Caron,et al.  Removal of phosphorylation sites from the β2-adrenergic receptor delays onset of agonist-promoted desensitization , 1988, Nature.

[161]  C. Malbon,et al.  N-glycosylation in expression and function of beta-adrenergic receptors. , 1986, The Journal of biological chemistry.